Company: ARTL
Filing Date: 2025-07-11
Form Type: S-1
Source: 0001640334-25-001190
Chunk: 19

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-07-11
Form: S-1
Chunk 19
---
 sales of Common Stock will have on its market price or the activities of short sellers. Sales involving significant amounts of Common Stock, including issuances made in the ordinary course of the Company’s business, or the perception that such sales could occur, may materially and adversely affect prevailing market prices of the Common Stock.

We have never paid dividends on our capital stock, and we do not anticipate paying dividends in the foreseeable future.

We have never paid dividends on any of our capital stock and currently intend to retain any future earnings to fund the growth of our business. We may also enter into credit agreements or other borrowing arrangements in the future that will restrict our ability to declare or pay cash dividends on our Common Stock. Any determination to pay dividends in the future will be at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. As a result, capital appreciation, if any, of the securities will be the sole source of gain, if any, for the foreseeable future.

| 9 |

The market price of our shares may be subject to fluctuation and volatility. You could lose all or part of your investment.

The market price of our Common Stock is subject to wide fluctuations in response to various factors, some of which are beyond our control. The market price of our shares on the Nasdaq Capital Market may fluctuate as a result of a number of factors, some of which are beyond our control, including, but not limited to:

| · | actual or anticipated variations in our and our competitors’ results of operations and financial condition                                                                      |
| · | changes in earnings estimates or recommendations by securities analysts, if our shares are covered by analysts;                                                                 |
| · | market acceptance of our product candidates;                                                                                                                                    |
| ● | our obligation to use commercially reasonable efforts to use $250,000 of the net proceeds from the Private Placement to purchase Solana, as required by the Purchase Agreement; |
| · | development of technological innovations or new competitive products by others;                                                                                                 |
| · | announcements of technological innovations or new products by us;                                                                                                               |
| · | publication of the results of preclinical or clinical trials for our product candidates;                                                                                        |
| · | failure by us to achieve a publicly announced milestone;                                                                                                                        |
| · | delays between our expenditures to develop and market new or enhanced products and the generation of sales from those products;                                                 |
| · | developments concerning intellectual property rights, including our involvement in